FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:959-961 March 1, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Evidence-based medicine assimilates available data to direct decisions regarding the care of patients. Extrapolations from epidemiologic observations and laboratory or clinical markers of disease severity have supported new treatments that were subsequently found to be without value in randomized, controlled clinical trials.¹ In addition, therapies considered to be beneficial and safe owing to their effect on surrogate markers have been found to be ineffective or harmful in such trials.^1,2 Even the results of randomized, controlled trials can be misleading, especially when the trials are not adequately powered.³

The use of erythropoietic agents to treat anemia in patients . . . [Full Text of this Article]

This article has been cited by other articles:

• Anand, I. S. (2008). Anemia and Chronic Heart Failure: Implications and Treatment Options. J Am Coll Cardiol 52: 501-511 [Abstract] [Full Text]  
• DeLoughery, T. G. (2007). Update in Hematology. ANN INTERN MED 147: 717-724 [Full Text]  
• Maddux, F. W, Shetty, S., del Aguila, M. A, Nelson, M. A, Murray, B. M (2007). Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease. The Annals of Pharmacotherapy 41: 1761-1769 [Abstract] [Full Text]  
• Ingelfinger, J. R. (2007). Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions. CJASN 2: 415-417 [Full Text]